Hasty Briefsbeta

Bilingual

Bi-Target Nanomodulator for Glioma-Associated Myeloid Cells Polarization by Inducing Pyroptosis and Regulating Tryptophan Metabolism to Reshape Immunosuppressive Microenvironment of IDH-Mutant Gliomas

4 hours ago
  • #immunotherapy
  • #nanomodulator
  • #glioma
  • A bi-target nanomodulator (LCC@GMM) is developed to enhance immunotherapy for IDH-mutant gliomas.
  • The nanomodulator uses a hybrid glioma-macrophage cell membrane for BBB penetration and dual homing to tumor cells and GAM.
  • It induces pyroptosis in tumor cells via ROS and La3+ release and regulates tryptophan metabolism in GAM via an AhR antagonist (CH223191).
  • This approach overcomes the immunosuppressive effects of IDH-mutant gliomas by reshaping the tumor microenvironment.
  • The study offers a novel strategy for immunotherapy targeting IDH-mutant gliomas.